MedTrace Logo

Corneal Uptake of Riboflavin Eye Drops

NCT04062435 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-03-31

No results posted yet for this study

Summary

The overall objective of this study is to optimise the corneal cross-linking standard protocol in terms of a more economical use of the resource "medical personnel" and in terms of increased patient participation. If it can be shown that the riboflavin necessary for corneal cross-linking does not necessarily have to be applied directly on the cornea (as currently performed by the nurses), but can also be applied in the inferior fornix (as it would be performed by patients in the context of self-application), then it would be conceivable to transfer this task from medical staff to the patients.

Conditions

  • Keratoconus

Interventions

DRUG

Drop application in the inferior fornix

See Arms

DRUG

Drop application on the cornea

See Arms

Sponsors & Collaborators

  • Luzerner Kantonsspital

    lead OTHER

Principal Investigators

  • Katja Iselin, MD · Dept. of Ophthalmology, Lucerne Cantonal Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2020-03-01
Completion
2020-03-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04062435 on ClinicalTrials.gov